Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Voyager Therapeutics (VYGR) Accumulated Depreciation & Amortization (2016 - 2025)

Voyager Therapeutics' Accumulated Depreciation & Amortization history spans 11 years, with the latest figure at $19.2 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 20.01% year-over-year to $19.2 million; the TTM value through Dec 2025 reached $19.2 million, up 20.01%, while the annual FY2025 figure was $19.2 million, 20.01% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $19.2 million at Voyager Therapeutics, up from $16.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $19.2 million in Q4 2025 and bottomed at $15.0 million in Q4 2023.
  • The 5-year median for Accumulated Depreciation & Amortization is $16.0 million (2024), against an average of $16.7 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization surged 37.54% in 2021 before it decreased 12.61% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $15.9 million in 2021, then grew by 8.13% to $17.2 million in 2022, then decreased by 12.61% to $15.0 million in 2023, then increased by 6.12% to $16.0 million in 2024, then rose by 20.01% to $19.2 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Accumulated Depreciation & Amortization are $19.2 million (Q4 2025), $16.0 million (Q4 2024), and $15.0 million (Q4 2023).